When treatment is undertaken with drugs which are known to be capable of causing anaphylactic shock, it is usual to keep the patient under observation for half an hour or so after the first dose has been given so that if symptoms of anaphylaxis should develop medical help will be immediately available. This is of great importance when drugs are given parenterally; especially if they are given intravenously. The appropriate treatment has recently been summarized (British Medical Journal 1981) . Severe and sometimes fatal anaphylactic shock can, however, occur from natural hazards -in particular, insect stings and snake bites. In the United Kingdom bee and wasp stings are by far the commonest causes and a small number of deaths is reported every year (Herbert 1981) .
Patients who have reacted badly to such stings should be told to keep insect killing sprays in every room in the house, including the lavatory and bathroom which are often forgotten. They should also be instructed to apply insect repellent creams to all exposed areas of skin whenever there is a risk that they may be stung. Furthermore, although immunotherapy using extracts of whole insect bodies is probably valueless (Lichtenstein et al. 1979) ,the use of bee and wasp venoms seems to be remarkably effective although the degree of protection provided and the duration of treatment required have still to be determined (Lichtenstein et al. 1979 , Frankland & Lessof 1981 . There is a growing body of evidence suggesting that any adult who has had a severe reaction to a bee or wasp sting should be referred to a centre where immunotherapy with hymenoptera venoms is available, for investigation for suitability for this type of treatment (Frankland & Lessor 198O, 1981 .
Patients are, of course, often stung in situations where medical help cannot rapidly be obtained. Moreover, the protection provided by immunotherapy, even when actual venoms are used, is incomplete so that a patient undergoing immunotherapy who suffers a number of stings on one occasion may develop anaphylaxis (Lichtenstein et al. 1979 , Frankland & Lessof 1981 . In consequence, physicians have tried to provide their patients with some form of treatment suitable for self-administration. Although the most effective emergency treatment is undoubtedly adrenaline by deep subcutaneous or 0141-0768/81/080567-03/$01.00/0 even intramuscular injection (see below), some patients will be considered unlikely to be able to inject themselves in an emergency. For such patients, other and simpler treatments have been recommended. These have included adrenaline as an aerosol for inhalation from pressurized canisters (Frankland & Lessof 1980 . Goldstein et al. 1969 , Ganderton 1979 . Lancet 1980 , and isoprenaline as an aerosol, similarly dispensed (Frankland & Lessof 1980 . Sublingual isoprenaline has also often been recommended (Freedman 1979 , Herbert 1981 , and see Torsney 1973 .
Paterson and colleagues (1968), using pressurized canisters containing isoprenaline, have shown that much of the drug is trapped in the mouth and throat, and Davies (1979) has estimated that less than 10% reaches the lungs. This is almost certainly true for all drugs administered in this way, the therapeutic efficacy of which depends on the very small amounts reaching the lungs.
Adrenaline by inhalation will certainly tend to relieve the bronchospasm in anaphylactic shock. It is, however, very rapidly metabolized in the lungs and unless given in large doses in high concentrations has little or no systemic effect (Innes & Nickerson 1975) . In fact. Urbach & Gottlieb (1946) recommended the inhalation of adrenaline as a treatment for asthma in order to avoid the cardiovascular effects of this drug when given by injection. Adrenaline as a pressurized aerosol is available as a Medihaler-Epi. Three inhalations in two minutes do not change the pulse rates of healthy volunteers (Ackroyd, unpublished) , nor does this dose cause a statistically significant increase in the urinary excretion of adrenaline (Hoehne et al. 1970 ). Even fifteen inhalations over a period of two minutes only raised the urinary excretion of adrenaline to one-tenth the level observed after 0.48 ml of I : 1000 adrenaline was given subcutaneously (Hoehne et al. 1970) . These observations were made on healthy individuals. It is probable that even smaller quantities would be absorbed by patients with anaphylactic shock with severe bronchospasm in whom the inspiratory flow of air required to carry the aerosol into the lungs would be restricted and in whom the changes in the smaller airways would diminish the access of the inhaled aerosol to the pulmonary vasculature. There is some evidence that atopic subjects develop allergic reactions to insect venoms more frequently than do non-atopic individuals (Miyachi et al. 1979 ). If anaphylaxis occurs in asthmatic patients being treated regularly with {3adrenergic agonist bronchodilators, the cardiovascular effects of inhaled adrenaline might be reduced because the adminstration of adrenergic agonist drugs reduces the numbers of available {3adrenergic receptors (Barnes 1981) . It seems clear from the evidence cited above that inhaled adrenaline as a pressurized aerosol, although it might relieve the bronchospasm, would be ineffective as a treatment for the other manifestations of anaphylactic shock.
Although isoprenaline by inhalation is a powerful bronchodilator, very little 'is absorbed when it is administered by this route. One inhalation from a pressurized canister delivering 500 J.Ig of tritiated isoprenaline per dose failed to cause the appearance of any detectable radioactivity in the arterial blood at the time when the pharmacological effect of the drug was at its greatest (Blackwell et al. 1974 , Davies 1979 . However, sufficient is absorbed after inhalation of a dose of this size to raise the pulse rate, although this effect varies greatly from one individual to another. In a series of 5 healthy volunteers the increase in heart rate produced by the inhalation of 440 J.Ig of isoprenaline varied from 10 to 74 beats per minute in different individuals (Paterson et al. 1968 ). However, in a group of asthmatic patients with a large element of reversible airways obstruction, each of whom inhaled between 1000J.Ig and 2000 J.Ig of isoprenaline, only half showed an increase in heart rate of more than 10 beats per minute and in one patient the inhalation of 2000 J.Ig (equivalent to five puffs from a Medihaler-Iso-forte) failed to cause any rise in the pulse rate (Conolly et al. 1971) .The reduced effect of inhaled isoprenaline on the heart rate in asthmatic patients is probably due in part to the mechanical factors discussed above in connection with the inhalation of adrenaline. However, other factors may be important. If the patient was already suffering from asthma and being treated with {3-adrenergic agonist bronchodilators then these, as already stated, will reduce the numbers of available fJ-agonist receptors. This will tend to reduce the cardiovascular effects, not only of inhaled adrenaline, as described above, but also of inhaled isoprenaline. Moreover, if the patient had been taking isoprenaline regularly as a treatment for pre-existing asthma a further factor might operate: Paterson and his colleagues (1968) have produced evidence suggesting that patients treated in this way may experience a build-up of a metabolite of isoprenaline, 3-0.methyl isoprenaline, which has fJ-blocking activity.
The importance of the factors outlined above in reducing the cardiovascular effects of inhaled isoprenaline has been demonstrated in a study of 5 asthmatic patients taking over twenty puffs a day from canisters delivering 440 J.Ig per dose. None of these patients developed any increase in heart rate until they inhaled 8 puffs at one time (i.e. over 3500 J.Ig) (Paterson et al. 1968) .
Just how greatly the actual absorption of a bronchodilator drug inhaled from a pressurized canister can vary from one individual to another has been strikingly shown in some unpublished work by Professor D S Davies (personal communication) who, using canisters containing terbutaline, found that the amount absorbed through the lungs in different individuals varied from 0.1% to 10% of the inhaled dose.
The absorption of isoprenaline administered sublingually seems to be equally variable (Innes & Nickerson 1975 , Stanzler 1966 ). Herxheimer (1952 and Schumann & Herxheimer (1971) have reported that the sublingual dose required for the relief of bronchospasm in asthma varied from about 2.5 mg to 80 mg in different patients, and several workers have commented on the danger of severe systemic reactions caused by isoprenaline administered by this route (Innes & Nickerson 1975 , Martindale 1972 , Minette 1971 , the danger presumably being due to the administration of large doses to patients who absorb it readily. Criscitiello (1968) has reported that as little as 5.0 mg of isoprenaline sublingually given as a treatment for heart block may produce ventricular tachycardia. A further disadvantage of the sublingual route is that the drug is absorbed much more slowly than when it is inhaled. This is probably because almost all the isoprenaline taken in this way is absorbed, not through the oral mucosa, but through the gastrointestinal tract, after being swallowed (D S Davies, personal communication).
It seems clear from the foregoing that the inhalation of adrenaline from a Medihaler-Epi has no place in the treatment of anaphylaxis. This seems also to be true for isoprenaline administered sublingually. Has inhaled isoprenaline any place? Terr (1980) has recently stated that neither adrenaline nor isoprenaline by inhalation is a reliable means of protection from anaphylactic shock. However, isoprenaline is absorbed by this route and is an even more potent inhibitor of histamine release from sensitized cells than is adrenaline (Schild 1973 , Lichtenstein 1973 . The problem is the .variable extent to which it is absorbed, so that a dose adequate for one patient might be dangerously high or totally ineffective for the next. Isoprenaline given by this route might be made both safe and effective, at least for patients who develop attacks of angioedema affecting the mouth and throat, if those individuals who also develop bronchospasm are excluded from this form of therapy. Patients with pre-existing asthma being treated regularly with large doses of fl-adrenergic agonist bronchodilators should probably also be excluded. Before being given a canister for self-administration, suitable patients should be investigated routinely to discover the dose he or she needs to inhale to raise the pulse rate by twenty to thirty beats per minute. If this dose was inhaled immediately the patient began to develop angioedema, an amount sufficient to abort the attack might be absorbed. The number of inhalations required should preferably be determined in specialist centres in order to exclude from this treatment the occasional patient who develops a dysrhythmia after inhaling quite small doses of isoprenaline.
It is generally agreed that the most effective initial treatment for any patient with anaphylaxis is adrenaline by deep subcutaneous or, if the patient is severely shocked, by intramuscular injection (see, for instance, Lancet 1980 , British Medical Journal 1981 , Frankland & Lessof 1980 , Lancaster 1980 . Patients who have just been stung and who have had a severe reaction in the past are usually frightened and may find themselves unable to open an ampoule and fill a syringe and then inject themselves during a time when their symptoms are increasing in severity. Syringes precharged with adrenaline have not recently been available in the UK (British Medical Journal 1979 , Brown 1980 , but now can be obtained easily (Ackroyd 1980) . It is strongly recommended that any patient who has had a severe reaction and who seems likely to be able to use such a syringe should be given one and taught how to use it. The dose of adrenaline with which the patient should inject himself should be determined in a manner similar to that suggested for determining the dose of inhaled isoprenaline. 
The infection-prone hospital patient
To those of us who remember pre-penicillin days, the achievements of antibiotics are nothing short of miraculous. We can now cure diseases like bacterial endocarditis and tuberculous meningitis which in those days were always lethal.
The impact of antibiotics in surgical practice, however, has been less dramatic and no amount of the newest and most expensive antibiotic can make up for bad surgery, or rescue the patient who is profoundly septic. The considerable new vocabulary embracing septic shock, shock lung and multiple organ failure is testimony to this.
Infections are caused by microorganisms whose number and virulence determine their aggres-
